FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome

SILVER SPRING, Md., Dec. 12, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA),... Biopharmaceuticals, FDA GlaxoSmithKline, Nucala, mepolizumab, eosinophilic granulomatosis, Churg-Strauss
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news